文献速递腹部CTPET

局部胰腺导管腺癌系统治疗后再分期:CT、FDG-PET与CA19-9作用的范围综述

Restaging the primary tumor in localized pancreatic ductal adenocarcinoma after systemic therapy: a scoping review of the role of CT, FDG-PET, and CA19-9.
PubMed 文献 · Eur Radiol · 2026-10-13

该范围综述纳入20项研究,评估局部胰腺导管腺癌系统治疗后基于CT和PET/CT再分期方法与可切除性、总生存及R0切除率的关联。结果显示各再分期方法与结局的关联不一致,RECIST 1.1对部分缓解和疾病稳定的评估尤其受限。证据提示整合额外影像特征、替代影像模态及CA19-9可能改善可切除性和预后评估。

要点

  • RECIST 1.1评估部分缓解和疾病稳定准确性有限,再分期需谨慎。
  • 现有再分期方法与R0切除及生存的关联不一致,无一致方法。
  • 可整合额外影像特征、PET/CT代谢参数及CA19-9辅助再分期。

核心结论

  • 局部PDAC系统治疗后RECIST 1.1对部分缓解和疾病稳定分类准确性有限,再分期仍具挑战。
  • 现有证据提示整合额外影像特征、替代影像模态及CA19-9可能改善可切除性和预后评估。

研究设计与样本

  • 范围综述,检索MEDLINE、Embase和CENTRAL,最终纳入20项研究。
  • 15项研究分析CT,5项分析PET/CT,评估系统治疗后再分期方法。

诊断标准与关键数值

  • 再分期方法包括新反应类别、基于大小的指标、体积、血管接触、肿瘤衰减、18F-FDG PET/CT代谢参数及可切除性标准。
  • 双能CT衍生细胞外体积(DECT-ECV)作为基线预测生物标志物被评估。
  • 再分期方法与结局的关联报告不一致,部分研究显示特定方法有显著关联而其他无。
  • 无再分期方法在所有研究中均显示与R0切除和生存的一致关联。

临床应用与阅片要点

  • 日常再分期阅片应警惕RECIST 1.1对部分缓解和疾病稳定的局限,避免仅凭大小变化判断。
  • 可结合血管接触、肿瘤衰减、PET/CT代谢参数及CA19-9综合评估可切除性。

局限性

  • 纳入研究方法异质性大,再分期方法与结局关联报告不一致。
  • 多数研究分析CT,PET/CT研究较少,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The introduction of improved multi-agent systemic therapies has made restaging and treatment response assessment in patients with localized pancreatic ductal adenocarcinoma (PDAC) increasingly complex. This scoping review aims to assess and compare methods for local disease restaging and treatment response assessment in localized PDAC, with a focus on their association with resectability, overall survival (OS), and R0-resection rates.

MATERIALS AND METHODS: This scoping review included studies on restaging in patients with PDAC following systemic therapy using CT and PET/CT from MEDLINE, Embase, and CENTRAL.

RESULTS: Among 4680 identified studies, 20 fulfilled the eligibility criteria. Most (n = 15) studies analyzed CT, and 5 analyzed PET/CT. Groups of restaging methods included new response categories, size-based metrics, volume, vascular contact, tumor attenuation, fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT derived metabolic parameters, and resectability criteria. Dual-energy CT-derived extracellular volume (DECT-ECV) was evaluated as a baseline predictive biomarker. Associations between restaging methods and outcomes were reported inconsistently: some studies found significant associations for specific methods, whereas others did not. No restaging method showed a consistent association with both R0-resection and survival across all studies.

CONCLUSION: Restaging of localized PDAC after systemic treatment remains challenging due to the limited accuracy of RECIST 1.1, particularly for the classifications partial response and stable disease. The current evidence suggests that integrating additional imaging features, alternative imaging modalities, and the biomarker carbohydrate antigen (CA)19-9 may improve the assessment of resectability and prognosis. These findings support a future version of RECIST 1.1 to alert clinicians to this issue.

KEY POINTS: Question How effective are current (PET/)CT-based restaging methods in assessing local disease resectability and prognosis in localized PDAC after modern multi-agent systemic therapy? Findings Current restaging methods show inconsistent association with R0-resection and survival; RECIST 1.1 is particularly limited for the assessment of partial response and stable disease. Clinical relevance Current evidence confirms a need to integrate additional imaging features and the biomarker CA19-9, during restaging in patients with localized pancreatic cancer after modern systemic therapy to improve accuracy and reduce the risk of missed treatment options.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lamoré AM, Kop MPM, Zamboni GA, et al. Restaging the primary tumor in localized pancreatic ductal adenocarcinoma after systemic therapy: a scoping review of the role of CT, FDG-PET, and CA19-9. Eur Radiol. 2026. PMID: 42867514. doi:10.1007/s00330-026-12954-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。